|
| | |
|
Am J Psychiatry 1995; 152:130-134
Copyright © 1995 by American Psychiatric Association
Improvement of some schizophrenic deficit symptoms with low doses of amisulpride
ML Paillere-Martinot, Y Lecrubier, JL Martinot and F Aubin
Department of Child and Adolescent Psychiatry, Hopital de la Salpetriere, Paris, France.
OBJECTIVE: The authors assessed the effects on primary negative symptoms of
low doses of amisulpride, a substituted benzamide neuroleptic with high
affinity for D2 and D3 dopamine receptors. METHOD: Young, drug-free
schizophrenic patients with pure negative symptoms participated in a 6-week
double-blind trial of placebo (N = 10) or low-dose amisulpride (N = 10).
They were assessed with the Scale for the Assessment of Negative Symptoms.
RESULTS: Amisulpride significantly improved negative symptoms. Improvement
in avolition, attentional impairment, and retardation was significantly
greater with amisulpride than with placebo. CONCLUSIONS: These findings
suggest that some primary negative symptoms may be directly affected by low
doses of benzamide neuroleptics.
This article has been cited by other articles:
|
|
|
|
 
A. A. Gibbs, K. H. Naudts, E. P. Spencer, and A. S. David
The Role of Dopamine in Attentional and Memory Biases for Emotional Information
Am J Psychiatry,
October 1, 2007;
164(10):
1603 - 1609.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. W. Buchanan
Persistent Negative Symptoms in Schizophrenia: An Overview
Schizophr Bull,
July 1, 2007;
33(4):
1013 - 1022.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Burton
Symptom domains of schizophrenia: the role of atypical antipsychotic agents.
J Psychopharmacol,
November 1, 2006;
20(6 Suppl):
6 - 19.
[Abstract]
[PDF]
|
|
|
|
|
|
|
C. la Fougere, E. Meisenzahl, G. Schmitt, J. Stauss, T. Frodl, K. Tatsch, K. Hahn, H.-J. Moller, and S. Dresel
D2 Receptor Occupancy During High- and Low-Dose Therapy with the Atypical Antipsychotic Amisulpride: A 123I-Iodobenzamide SPECT Study
J. Nucl. Med.,
June 1, 2005;
46(6):
1028 - 1033.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. L. Barrett, R. Bell, D. Watson, and D. J. King
Effects of Amisulpride, Risperidone and Chlorpromazine on Auditory and Visual Latent Inhibition, Prepulse Inhibition, Executive Function and Eye Movements in Healthy Volunteers
J Psychopharmacol,
June 1, 2004;
18(2):
156 - 172.
[Abstract]
[PDF]
|
|
|
|
|
|
|
S. Leucht, G. Pitschel-Walz, R. R. Engel, and W. Kissling
Amisulpride, an Unusual ""Atypical"" Antipsychotic: A Meta-Analysis of Randomized Controlled Trials
Am J Psychiatry,
February 1, 2002;
159(2):
180 - 190.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Kapur and P. Seeman
Does Fast Dissociation From the Dopamine D2 Receptor Explain the Action of Atypical Antipsychotics?: A New Hypothesis
Am J Psychiatry,
March 1, 2001;
158(3):
360 - 369.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
J.-M. Danion, W. Rein, O. Fleurot, and the Amisulpride Study Group
Improvement of Schizophrenic Patients With Primary Negative Symptoms Treated With Amisulpride
Am J Psychiatry,
April 1, 1999;
156(4):
610 - 616.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
C. Trichard, M.-L. Paillére-Martinot, D. Attar-Levy, C. Recassens, F. Monnet, and J.-L. Martinot
Binding of Antipsychotic Drugs to Cortical 5-HT2A Receptors: A PET Study of Chlorpromazine, Clozapine, and Amisulpride in Schizophrenic Patients
Am J Psychiatry,
April 1, 1998;
155(4):
505 - 508.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
H. Schoemaker, Y. Claustre, D. Fage, L. Rouquier, K. Chergui, O. Curet, A. Oblin, F. Gonon, C. Carter, J. Benavides, et al.
Neurochemical Characteristics of Amisulpride, an Atypical Dopamine D2/D3 Receptor Antagonist with Both Presynaptic and Limbic Selectivity
J. Pharmacol. Exp. Ther.,
January 1, 1997;
280(1):
83 - 97.
[Abstract]
[Full Text]
|
|
|
Get information about faster international access.
Privacy Policy
Copyright © 1995
American Psychiatric Association.
All rights reserved.
Home
| Search
| Current Issue
| Past Issues
| Subscribe
| All APPI Journals
| Help
| Contact Us
|
